FOLLOW US

Tech billionaire Elon Musk’s company, Neuralink, has announced that its experimental Blindsight implant has received “breakthrough device” designation from the Food and Drug Administration (FDA). 

 According to Musk, the implant may enable individuals who have lost both eyes and even their optic nerve to regain some form of sight. He emphasized that the implant could potentially give those who have been blind since birth the ability to see for the first time, provided they have an intact visual cortex.

https://youtu.be/U_-b8uiBT6I

Blindsight is a Breakthrough

Manufacturers granted the breakthrough device designation are given “an opportunity to interact with FDA experts” to expedite the development and approval process, helping address regulatory issues early in the review phase. 

This designation is reserved for medical devices with the potential to provide groundbreaking benefits, such as restoring vision for those who have lost it due to injury or degenerative conditions.

The FDA also prioritizes these devices for premarket evaluation. In 2023 alone, 145 medical devices received this designation, underscoring its significance in fast-tracking critical advancements in medical technology.

What Blindsight Could Mean for Vision Loss

Neuralink’s Blindsight device holds the promise of vision restoration for those who are entirely blind. 

Musk’s statements suggest that Blindsight could initially offer a low-resolution visual experience, which he compared to “early Nintendo graphics.”

However, he expressed optimism that future developments may exceed natural human vision, with potential abilities to perceive infrared, ultraviolet, or even radar wavelengths.

The device is still in the developmental phase, with Neuralink working to improve its capabilities. 

While Neuralink has made strides, some experts remain cautious about Blindsight’s potential impact.

 According to TechCrunch, restoring sight for individuals blind since birth may be challenging because those who have never developed visual processing capabilities lack the necessary biological foundation for sight restoration.

A Parallel Technology: Telepathy

In addition to Blindsight, Neuralink is working on another implant known as “Telepathy,” which allows individuals with spinal cord injuries to control computers with their thoughts.

 Recently, a second human patient received this implant. Early demonstrations suggest that individuals with Telepathy can perform tasks like playing video games or designing 3D objects solely through neural signals.

Despite these technical and regulatory hurdles, interest in the company's advancements remains high, with over 1,000 human volunteers signed up for its second round of surgical trials. 

Musk stated that Neuralink intends to implant up to eight more patients with its Telepathy technology by the end of 2024. 

There is growing interest in the technologies Musk has pioneered.

Testing in Monkeys

According to Musk, Telepathy has already demonstrated functionality in monkeys. This achievement is significant, although it has raised some concerns. 

Neuralink animal testing practices have reportedly drawn scrutiny from federal investigators, but Musk maintains that “no monkey has died or been seriously injured by a Neuralink device.”

Blindsight and Telepathy reflect Elon Musk's ambitious vision for neurotechnology, but the road ahead is complex.

While the FDA’s designation is a promising step, the company must address regulatory, technical, and ethical issues as it seeks to bring these devices to the public.